Adjuvant therapy
MINDACT Trial: Outcome of Patients with UltraLow Risk, JCO 2022
Journal of Clinical Oncology, Volume 40, Number 12, January 21, 2022 Authors: Audeh et al.
Read MoreWhole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients ≤ 50 years and > 50 years
PUBLICATION: ASCO 2021 Authors Cathy Graham1, Douglas K. Read More
MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer
PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Read More
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial
PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Read More
Controlling Technical Variation Amongst 6693 Patient Microarrays of the Randomized MINDACT Trial
PUBLICATION: Communications Biology AUTHORS: Laurent Jacob, Anke Witteveen, Inès Beumer, Read More
ASCO 2020: 8q22 Poster
PUBLICATION: ASCO 20 AUTHORS: Sami Diab, Matei P. Socoteanu, Carlos Read More
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
PUBLICATION: Soliman et al. BMC Cancer (2020) 20:81 AUTHORS: Hatem Read More
SABCS 2019: Cyclin E Expression
AUTHORS: Lorenza Mittempergher, Joseph McKelley, Rajith Bhaskaran, Sahra Uygun, René Read More
SABCS 2019: PROMIS Clinical Risk
AUTHORS: Michaela Tsai, Hatem Soliman, Shelly Lo, Rubina Qamar, Raye Read More
Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial
PUBLICATION: Acta Medica Academica. Volume 48 (2) August 2019 AUTHOR: Read More
